Dose of cyanocobalamin, renal function and reduction of stroke or cardiovascular events
| Trial | Dose of cyanocobalamin | Serum creatinine (μmol/L*) (SD or 95% CI) | HR of stroke (95% CI) | P value | |
| Active | Control | ||||
| DIVINe | 1000 mcg | 141.4 (97.2) | 123.8 (79.6) | 6.6 (0.8 to 54.4) | 0.08 |
| VISP | 400 mcg | 99.9 (55.7) | 97.2 (47.7) | 1.0 (0.8 to1.3) | 0.8 |
| VITATOPS | 500 mcg | 92.4 (40.3) | 91.4 (34.6) | 0.92 (0.81 to 1.06) | 0·25 |
| NORVIT | 400 mcg | 91 (27) | 91 (24) | 0.83 (0.47 to 1.47) | 0.52 |
| HOPE 2 | 1000 mcg | 88.4 (26.5) | 88.4 (26.5) | 0.75 (0.59 to 0.97) | 0.03 |
| SU.Fol.OM3 | 20 mcg | 78.0 (70.0 to 88.0) | 78.0 (69.0 to 88.0) | 0.57 (0.33 to 0.97) | 0.04 |
| CSPPT with eGFR<60 | 0 mcg | 126.6 (72.7) | 130.6 (68.6) | 0.88(0.33 to 2.36) | 0.81 |
| CSPPT with eGFR > 60 | 0 mcg | 64.7 (13.8) | 64.6 (13.6) | 0.79(0.67 to 0.92) | 0.003 |
DIVINe, Diabetic Intervention witih Vitamins in Diabetic Nephropathy; VISP, Vitamin Intervention for Stroke Prevention; VITATOPS, Vitamins to Prevent Stroke; HOPE 2, Heart Outcomes Prevention Evaluation 2; Su.Fo.OM3, SUpplementation with FOlate, vitamin B6 and B12 and/or OMega-3 fatty acidsl; CSPPT, China Stroke Primary Prevention Trial
*Conversions from mg/dL performed using http://www.endmemo.com/medical/unitconvert/Creatinine.php 44
eGFR, estimated glomerular filtration rate; HOPE, Heart Outcomes Prevention Evaluation; NORVIT, Norwegian Vitamin Trial; VISP, Vitamin Intervention for Stroke Prevention.